Hypertension Risk Factors: Non-Modifiable and Modifiable Causes of High Blood Pressure

Hypertension (HTN) affects ~1.3 billion adults globally. It arises from interacting genetic, environmental, and lifestyle factors. Identifying modifiable risks enables prevention and control.

Non-Modifiable Risk Factors

  • Age: Arterial stiffening → ↑ systolic BP; prevalence >60% at age 60+
  • Genetics/Family history: Polygenic; ~30–50% heritable; GWAS identifies >1,000 loci
  • Race/Ethnicity: Black adults: earlier onset, higher severity, salt sensitivity, worse outcomes (driven by structural/social determinants)
  • Sex: Men <65 > women; post-menopause women catch up or surpass

Modifiable Risk Factors

  • Obesity (BMI ≥30): ↑ insulin resistance → renal Na⁺ retention → ↑ volume; adipokines, SNS activation; weight loss 5–10% → ↓5–20 mmHg systolic
  • Physical inactivity: ↑ SNS, ↓ NO, ↑ stiffness; 150 min/week moderate → ↓4–9 mmHg
  • Diet:
    • High sodium (>2.3g/day Na⁺) → volume expansion
    • Low potassium (<3.5g/day) → ↓ natriuresis
    • Low fruit/veg (DASH diet ↓11 mmHg systolic)
    • Alcohol: >2 drinks/day men, >1 women → ↑ BP dose-dependently
  • Tobacco: Acute vasoconstriction; chronic endothelial dysfunction
  • Sleep apnea: Intermittent hypoxia → SNS/RAAS activation; CPAP ↓ BP
  • Stress: Chronic SNS/HPA activation; psychosocial stressors

Secondary Hypertension (5–10% of Cases)

  • Chronic kidney disease (most common)
  • Primary aldosteronism (screen if resistant HTN)
  • Renovascular disease, Cushing's, pheochromocytoma, thyroid/parathyroid disorders
  • Drug-induced: NSAIDs, oral contraceptives, steroids, stimulants, licorice, immunosuppressants

Clinical Approach

  1. Accurate measurement (validated device, proper technique, average ≥2 readings on ≥2 visits)
  2. Assess global CV risk (ASCVD score, target organ damage)
  3. Screen for secondary causes if resistant, young, hypokalemic, or suggestive features
  4. Lifestyle prescription first (unless Stage 2 or high risk)
  5. Pharmacotherapy per guideline (ACEi/ARB, CCB, thiazide, β-blocker)

Hypertension is the leading modifiable risk factor for CVD. Population-level sodium reduction and individual risk factor control are public health priorities.

Hypertension - Related Articles